Literature DB >> 29769911

Canada's Vaccine Vigilance Working Group.

N Ahmadipour1, E Toth2, B J Law1.   

Abstract

The Vaccine Vigilance Working Group (VVWG) was created in 2004 as part of the National Immunization Strategy to strengthen vaccine safety in Canada. The Group has representation from all federal/provincial/territorial immunization programs across the country, as well as Health Canada regulators and the Immunization Monitoring Program ACTive (IMPACT) network. VVWG works to harmonize vaccine safety monitoring and adverse event reporting and management across Canada by developing and following national guidelines and seeking out best pharmacovigilance practices, including training. It also provides a national vaccine safety sentinel network that uses several mechanisms to rapidly share information on emerging safety issues to enable effective public health response. The "vigilance" in VVWG emphasizes the watchful, ever alert nature and activities of the Group's work. Increased public and health professional awareness of the VVWG's role and activities should help to allay concerns about vaccine safety that lead to vaccine hesitancy and in turn limit the effectiveness of immunization.

Year:  2014        PMID: 29769911      PMCID: PMC5868593          DOI: 10.14745/ccdr.v40is3a05

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  2 in total

1.  Behind the scenes in public health: Adverse events following immunization (AEFI) signal investigation in British Columbia.

Authors:  L MacDonald; M Naus
Journal:  Can Commun Dis Rep       Date:  2014-12-04

2.  Analyzing and strengthening the vaccine safety program in Manitoba.

Authors:  J M Montalban; C Ogbuneke; T Hilderman
Journal:  Can Commun Dis Rep       Date:  2014-12-04
  2 in total
  2 in total

1.  Vaccine vigilance in Canada: Is it as robust as it could be?

Authors:  P Duclos
Journal:  Can Commun Dis Rep       Date:  2014-12-04

2.  Analyzing and strengthening the vaccine safety program in Manitoba.

Authors:  J M Montalban; C Ogbuneke; T Hilderman
Journal:  Can Commun Dis Rep       Date:  2014-12-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.